In a report released today, Elemer Piros from Cantor Fitzgerald maintained a Hold rating on Bluebird Bio (BLUE), with a price target of $122. The company’s shares closed yesterday at $156.18.
Piros commented:
“We rate bluebird bio Neutral. BLUE, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for rare severe genetic diseases. Its product candidates include Lenti-D, which is in a pivotal clinical study for the treatment of cerebral adrenoleukodystrophy; LentiGlobin, which is in clinical studies for the treatment of beta thalassemia major and severe sickle cell disease (SCD); and bb2121 and bb21217 CAR-T candidates in multiple myeloma. Valuation Summary We value bluebird bio based on a risk-adjusted NPV calculation of its clinical pipeline.”
According to TipRanks.com, Piros is a 2-star analyst with an average return of 0.1% and a 47.8% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Proteostasis Therapeutics Inc.
Bluebird Bio has an analyst consensus of Moderate Buy, with a price target consensus of $158.40.
See today’s analyst top recommended stocks >>
The company has a one-year high of $199.70 and a one-year low of $87.49. Currently, Bluebird Bio has an average volume of 546.5K.
Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217.
